Mineral and bone disorder in Chinese dialysis patients: a multicenter study

<p>Abstract</p> <p>Background</p> <p>Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patie...

Full description

Bibliographic Details
Main Authors: Kong Xianglei, Zhang Luxia, Zhang Ling, Chen Nan, Gu Yong, Yu Xueqing, Liu Wenhu, Chen Jianghua, Peng Liren, Yuan Weijie, Wu Hua, Chen Wei, Fan Minhua, He Liqun, Ding Feng, Chen Xiangmei, Xiong Zuying, Zhang Jinyuan, Jia Qiang, Shi Wei, Xing Changying, Tang Xiaoling, Hou Fanfan, Shu Guiyang, Mei Changlin, Wang Li, Xu Dongmei, Ni Zhaohui, Zuo Li, Wang Mei, Wang Haiyan
Format: Article
Language:English
Published: BMC 2012-09-01
Series:BMC Nephrology
Subjects:
Online Access:http://www.biomedcentral.com/1471-2369/13/116
id doaj-e480c83a3cff46809e46375917de6970
record_format Article
spelling doaj-e480c83a3cff46809e46375917de69702020-11-24T21:11:28ZengBMCBMC Nephrology1471-23692012-09-0113111610.1186/1471-2369-13-116Mineral and bone disorder in Chinese dialysis patients: a multicenter studyKong XiangleiZhang LuxiaZhang LingChen NanGu YongYu XueqingLiu WenhuChen JianghuaPeng LirenYuan WeijieWu HuaChen WeiFan MinhuaHe LiqunDing FengChen XiangmeiXiong ZuyingZhang JinyuanJia QiangShi WeiXing ChangyingTang XiaolingHou FanfanShu GuiyangMei ChanglinWang LiXu DongmeiNi ZhaohuiZuo LiWang MeiWang Haiyan<p>Abstract</p> <p>Background</p> <p>Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patients are extremely limited.</p> <p>Methods</p> <p>A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined.</p> <p>Results</p> <p>Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statistically higher (P < 0.05) in the HD patients compared with those of PD patients, which was (6.3 ± 2.1) mg/dL vs (5.7 ± 2.0) mg/dL and (9.3 ± 1.1) mg/dL vs (9.2 ± 1.1) mg/dL, respectively. Serum iPTH level were statistically higher in the PD patients compared with those of HD patients (P = 0.03). The percentage of patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%, P < 0.01) and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01) were lower among HD patients, compared with the data from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia.</p> <p>Conclusions</p> <p>Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of hyperphosphatemia is prominent and needs further attention.</p> http://www.biomedcentral.com/1471-2369/13/116End stage renal diseaseMineral and bone disorderEpidemiology
collection DOAJ
language English
format Article
sources DOAJ
author Kong Xianglei
Zhang Luxia
Zhang Ling
Chen Nan
Gu Yong
Yu Xueqing
Liu Wenhu
Chen Jianghua
Peng Liren
Yuan Weijie
Wu Hua
Chen Wei
Fan Minhua
He Liqun
Ding Feng
Chen Xiangmei
Xiong Zuying
Zhang Jinyuan
Jia Qiang
Shi Wei
Xing Changying
Tang Xiaoling
Hou Fanfan
Shu Guiyang
Mei Changlin
Wang Li
Xu Dongmei
Ni Zhaohui
Zuo Li
Wang Mei
Wang Haiyan
spellingShingle Kong Xianglei
Zhang Luxia
Zhang Ling
Chen Nan
Gu Yong
Yu Xueqing
Liu Wenhu
Chen Jianghua
Peng Liren
Yuan Weijie
Wu Hua
Chen Wei
Fan Minhua
He Liqun
Ding Feng
Chen Xiangmei
Xiong Zuying
Zhang Jinyuan
Jia Qiang
Shi Wei
Xing Changying
Tang Xiaoling
Hou Fanfan
Shu Guiyang
Mei Changlin
Wang Li
Xu Dongmei
Ni Zhaohui
Zuo Li
Wang Mei
Wang Haiyan
Mineral and bone disorder in Chinese dialysis patients: a multicenter study
BMC Nephrology
End stage renal disease
Mineral and bone disorder
Epidemiology
author_facet Kong Xianglei
Zhang Luxia
Zhang Ling
Chen Nan
Gu Yong
Yu Xueqing
Liu Wenhu
Chen Jianghua
Peng Liren
Yuan Weijie
Wu Hua
Chen Wei
Fan Minhua
He Liqun
Ding Feng
Chen Xiangmei
Xiong Zuying
Zhang Jinyuan
Jia Qiang
Shi Wei
Xing Changying
Tang Xiaoling
Hou Fanfan
Shu Guiyang
Mei Changlin
Wang Li
Xu Dongmei
Ni Zhaohui
Zuo Li
Wang Mei
Wang Haiyan
author_sort Kong Xianglei
title Mineral and bone disorder in Chinese dialysis patients: a multicenter study
title_short Mineral and bone disorder in Chinese dialysis patients: a multicenter study
title_full Mineral and bone disorder in Chinese dialysis patients: a multicenter study
title_fullStr Mineral and bone disorder in Chinese dialysis patients: a multicenter study
title_full_unstemmed Mineral and bone disorder in Chinese dialysis patients: a multicenter study
title_sort mineral and bone disorder in chinese dialysis patients: a multicenter study
publisher BMC
series BMC Nephrology
issn 1471-2369
publishDate 2012-09-01
description <p>Abstract</p> <p>Background</p> <p>Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patients are extremely limited.</p> <p>Methods</p> <p>A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined.</p> <p>Results</p> <p>Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statistically higher (P < 0.05) in the HD patients compared with those of PD patients, which was (6.3 ± 2.1) mg/dL vs (5.7 ± 2.0) mg/dL and (9.3 ± 1.1) mg/dL vs (9.2 ± 1.1) mg/dL, respectively. Serum iPTH level were statistically higher in the PD patients compared with those of HD patients (P = 0.03). The percentage of patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%, P < 0.01) and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01) were lower among HD patients, compared with the data from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia.</p> <p>Conclusions</p> <p>Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of hyperphosphatemia is prominent and needs further attention.</p>
topic End stage renal disease
Mineral and bone disorder
Epidemiology
url http://www.biomedcentral.com/1471-2369/13/116
work_keys_str_mv AT kongxianglei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT zhangluxia mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT zhangling mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT chennan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT guyong mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT yuxueqing mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT liuwenhu mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT chenjianghua mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT pengliren mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT yuanweijie mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT wuhua mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT chenwei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT fanminhua mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT heliqun mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT dingfeng mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT chenxiangmei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT xiongzuying mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT zhangjinyuan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT jiaqiang mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT shiwei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT xingchangying mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT tangxiaoling mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT houfanfan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT shuguiyang mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT meichanglin mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT wangli mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT xudongmei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT nizhaohui mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT zuoli mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT wangmei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
AT wanghaiyan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy
_version_ 1716753300082130944